Fierce JPM Week 2025 - Virtual

This panel will explore how agentic AI and human intelligence will transform drug development, from early-stage discovery and target identification to optimizing clinical trials and advancing personalized treatments. Key topics include AI’s role in accelerating research, improving trial design, and enhancing patient recruitment. The discussion will also address the challenges of understanding complex biology, ensuring data quality, and fostering cross-industry collaboration. By harnessing collective intelligence, the panel will highlight how these technologies can drive innovation, efficiency, and personalization across the drug development pipeline by harnessing collective intelligence.

With advancements in platform technologies and automation, the cell and gene therapy space is poised for changes. During this panel discussion, industry leaders will explore challenges and share insights on navigating regulatory hurdles, optimizing manufacturing and leveraging emerging technologies to address broader disease states.

Ecolab EVP Hayley Crowe talks with former Catalent CEO John Chiminski on what it takes to improve manufacturing cost and reduced risk profile while improving sustainability.

Adare CEO Tom Sellig talks with former Catalent CEO John Chiminski on why oral small molecules remains an important and attractive market segment

In an age of geopolitical tensions, Bora CEO Bobby Sheng talks with Fierce about bulding a new mega CDMO that provides global reliable supply

As healthcare embraces a more connected future, the need for real-time, global data access has become vital to bridging gaps in patient care and streamlining drug development. This panel delves into the challenges and opportunities in democratizing healthcare data, with a focus on integrated solutions and strategies that address data fragmentation and enable swift access to diverse patient and provider demographics. Join us to discover how democratizing healthcare data will shape the future of global patient care and catalyze advancements in the biopharma industry.

The biotech market made a comeback in 2024, recovering from a slump a year earlier. What will the IPO window look like in 2025? During this panel discussion, we will examine the performance of companies that went public in the second half of 2024 and how their success or challenges are impacting other startups’ decisions on whether to go public themselves

In the dynamic world of biotech, incubators, accelerators, and co-working spaces have become crucial ecosystems that nurture the growth of early-stage biotech companies. These innovative environments are designed to help emerging companies overcome the myriad challenges they face in developing groundbreaking therapies and diagnostics that enhance health outcomes.

As a biotech entrepreneur or stakeholder, you understand the importance of minimizing large capital investments in infrastructure and lab space. The bio-innovation ecosystem does just that, while simultaneously fostering a collegial atmosphere that sparks creativity and collaboration. Within this ecosystem, some hosts offer shared core lab facilities, coaching, guidance, and access to investment, all of which are pivotal to your success.

Join us for an exclusive fireside chat with Matt Dunleavy, Director of Global Commercial Strategy, and Mark Federici, Global Director of Bio-innovation at Thermo Fisher Scientific’s Biosciences business. This is your opportunity to gain insights into the capabilities and value that your choice of supplier can potentially bring to the ecosystem. Through real-world case studies, you will learn how biotech incubators have effectively collaborated with Thermo Fisher to achieve remarkable outcomes.

Don’t miss this chance to discover how you can leverage these collaborations to propel your biotech ventures forward.

Across the medtech industry, some of the largest players have shed entire divisions as they seek to narrow their focus on their core businesses. These moves range from J&J spinning out its Kenvue consumer operations, to Baxter selling off its multibillion-dollar kidney care unit, to GE HealthCare keeping the name of its conglomerate parent as it became an independent company. During this panel, we’ll explore the forces driving these divestitures and their effects on competition, branding, M&A and the broader market landscape—as well as whether elder firms have found success with smaller portfolios, and if the newcomers have found their footing.